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This is a novel case of a patient with a pigmented
vulvar lesion who was referred to a dermatologist
by her gynecologist to determine a follow-up
strategy for this lesion and consider a complete
resection to rule out melanoma. This lesion was
later discovered, through further examination and
histologic analysis, to be the result of mucosal
minocycline deposition.
CASE REPORT
A 67-year-old white woman presented to the
dermatology clinic for further assessment of a
pigmented vulvar lesion near the urethral meatus
that was discovered incidentally 4 months prior. The
patient had been examined by 3 gynecologists since
discovery of this lesion, which consisted of mostly
black pigmentationwith some various shades of grey
(Fig 1). A punch biopsy section taken by the second
gynecologist showed findings of spongiosis within
the epithelium with moderate to numerous
superficial melanophages (Fig 2). The differential
diagnosis included postinflammatory hyperpigmen-
tation, fixed drug eruption, and irritant contact
dermatitis, but a regressed mucosal melanoma was
also considered. The third gynecologist started the
patient on local estrogen therapy for severe vulvo-
vaginal atrophy and pain, which resulted in a fading
of the lesion from a black to grey color along with
resolution of the atrophic tissues. The patient did not
want to proceed with an additional biopsy at that
time, but when the lesion remained unchanged afterthe Departments of Dermatologya and Obstetrics and
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biopsy of the vulvar lesion at a site distal from the first
biopsy location. Similar histologic results to the first
biopsy were found. The patient was referred to
the dermatology clinic for consultation regarding
whether to perform scouting biopsies or full
resection to completely rule out melanoma.
Physical examination of the patient’s vulvar vestibule
displayed irregular grey patches of pigmentation,
which were not erythematous or tender, with
uniform pigment distribution under dermoscopy.
The pigmentation extended over the urethra, onto
the lateral surrounding vestibule, and against the
posterior vaginal wall. The skin examination was
also significant for widespread, irregular speckled
macules of varying shades of grey and small patches
of dyspigmentation throughout the patient’s body,
most notably on her legs, arms, eyes and face (Fig 3),
which was also observed by her third gynecologist.
The patient’s medical history was significant for
vaginal atrophy, hypothyroidism, and high choles-
terol. She also had cystic acne that she was treating
with minocycline consistently for the last 7 years but
also noted intermittent use for last 20 years. The
minocycline was prescribed by both her outside
dermatologist and primary care physician.
Iron stain of her prior tissue biopsy section was
recommended to look for possible minocycline
deposition given the patient’s extended minocycline
use and widespread cutaneous pigmentation.
Results of this iron staining were positive and
consistent with minocycline superficial dermalAvenue, LKS 3500, Cleveland, OH 44106-5028. E-mail: mathew.
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Fig 1. Minocycline pigmentation of the vulva. Irregular
pigmentation patch seen on the patient’s vulva during
examination.
Fig 2. Histopathologic findings from the pigmented
lesion biopsy taken from the vestibule/periurethral area.
Spongiosis of the epithelium and moderate to numerous
superficial melanophages were seen on histology.
(Hematoxylin-eosin stain; original magnification: 320.)
Fig 4. Histopathologic findings from the prior biopsy after
staining with iron. The biopsy section shows positive areas
of black and brown pigment in the papillary dermis
consistent with minocycline dermal pigmentation. (Iron
staining; original magnification: 340.)
Fig 3. Left forearm examination shows a small portion of
the widespread, irregular speckled macules and patches of
grey dyspigmentation present diffusely throughout the
patient’s skin surface.
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remaining within the patient’s vulvar vestibule was
found to be not related to amelanoma andwould not
require future surveillance biopsies. The patient was
instructed to cease further use of minocycline. She
switched to tretinoin 0.025% cream and clindamycin
1% lotion for her new acne regimen. At follow-up
2 months later, the patient already noticed reduction
of her minocycline-induced pigmentation on her
face, arm, and legs.
DISCUSSION
Minocycline is frequently used in dermatology
and is more lipophilic compared with other tetracy-
cline group members.1 Minocycline binds to plasma
proteins and has a propensity for depositing into soft
tissues rich with collagen. This lipophilic nature
allows for an extended half-life that conversely leadsto its higher incidence of adverse effects seen with
long-term treatments.2 One of the common adverse
effects with extended use is a blue-black/grey
pigmentation of the skin, which stems from
the oxidation of the aromatic D-ring within the
minocycline structure that forms a paraquinone
imine that has similar properties to that of the
quinone present in eumelanin.3,4
Minocycline hyperpigmentation is divided into 3
types. Type I is the most common and appears as
blue-black/grey pigment staining in areas of acne
scarring or inflammation as seen in this patient.5
Type II appears as blue-grey pigment on normal skin
most commonly on the shins, legs, and forearms,
also seen in this patient. Type III presents as diffuse
muddy-brown discoloration on sun-exposed areas
of the skin. Both types I and II stain for iron and
melanin on hematoxylin-eosin and resolve slowly
over time after minocycline is stopped. Type III
stains for melanin only and remains indefinitely.3 In
our patient case, a type I hyperpigmentation was
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inflammation associated with her vaginal atrophy,
resulting in progressive minocycline deposition
in the dermis as seen on histology. This case
distinguishes itself from a possible lichen sclerosis
condition, which can also cause vaginal atrophy and
hyperpigmentation but hyperpigmentation seen in
lichen sclerosis present in the epidermis.6
Because of the uniqueness of this pigmented
lesion’s location, a possible vulvar melanoma could
not be definitively ruled out before referral to the
dermatology clinic, thus, leaving the patient with
options of ongoing future visits involving multiple
random biopsies or possible complete resection
of the lesion. The concern of possible vulvar
melanoma, although rare, was warranted because it
is an aggressive tumor that accounts for less than 1%
of all malignant melanomas and carries a poor
prognosis, with a 5-year survival rate of 5% to
25%.7,8 After the patient’s dermatology referral visit
and subsequent discussion between dermatology,
dermatopathology, and gynecology departments,
this patient’s biopsy slides were re-examined with
iron staining, which showed the minocycline
deposition. The patient was give assurance that her
vulvar pigmentation was not melanoma and would
not require further biopsies or a complete resection.This patient’s case not only highlights this novel
presentation of vulvar minocycline pigmentation but
also emphasizes how management and therapy can
be maximized when colleagues between specialties
partner together during unique and challenging
cases for the betterment of care.
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